StockWatch
·
Computers - Software & Consulting
Board Meeting28 Jul 2026, 03:54 pm

Birlasoft Q1: consolidated PAT +51% YoY to ₹161 Cr on margins & tax; revenue up just 7%

AI Summary

Birlasoft reported consolidated net profit of ₹161.0 Cr for Q1 FY27, up 51.3% from ₹106.4 Cr a year ago but down 8.5% sequentially from Q4's ₹175.9 Cr. Revenue from operations rose 7.4% YoY (2.3% QoQ) to ₹1,379.4 Cr. Net margin expanded to 11.7% from 8.1% a year earlier, though it eased from 13.1% in Q4; consolidated EPS was ₹5.72 versus ₹3.81 YoY. The headline profit jump overstates operational momentum. Pre-tax profit grew a more measured 37.3% YoY (₹228.2 Cr vs ₹166.2 Cr), with the rest of the 51% PAT gain coming from a lower effective tax rate — 29.4% this quarter against 35.9% in a year-ago base that had been depressed by heavier tax and thin margins. There was no exceptional item this quarter (the ₹40.7 Cr labour-code charge that clipped FY26 sat in the full-year accounts, not in either compared quarter), so reported and underlying YoY growth are the same number. All four verticals grew revenue YoY — BFSI +12.1% to ₹351.0 Cr and Life Sciences segment profit jumping to ₹51.7 Cr from ₹30.2 Cr in Q4 — while Manufacturing, the largest vertical at ₹518.2 Cr, slipped 1.6% sequentially. The print broadly meets management's Q4 concall framing: guidance flagged EBITDA margins normalising to a 'sustainable 15%+' from Q4's 18.5% as the company funds a 30-40% sales-team expansion and an 'AI First' pivot, and operating margin (~14.7% this quarter) did step down QoQ as signalled while holding near that zone. Management gave no formal FY27 revenue guidance, citing volatility, and the modest 7.4% YoY topline is consistent with the cautious, bearish tone of that call — the projected 'eventual return to revenue growth' has yet to accelerate. Standalone results read far stronger (revenue +32% YoY to ₹829.2 Cr, net profit nearly quadrupling to ₹146.8 Cr), but that reflects parent-level and intra-group flows rather than operations; the consolidated figures are the operative measure and readers should not mistake the standalone jump for underlying performance. The results were approved at the July 28 board meeting and declared alongside a final dividend (record date July 10), with an earnings call the same evening. No published street consensus for the quarter was available at print. The setup into Q2 hinges on whether the sales-force build-out and AI positioning convert the modest topline into faster bookings, and whether the ~15% margin floor holds through the investment phase.

Key Highlights

  • Consolidated PAT ₹161.0 Cr, +51.3% YoY (from ₹106.4 Cr) but −8.5% QoQ (from ₹175.9 Cr in Q4)
  • Revenue from operations ₹1,379.4 Cr, +7.4% YoY and +2.3% QoQ — modest topline growth
  • Net margin 11.7% (up from 8.1% YoY, down from 13.1% QoQ); PBT rose 37.3% YoY, with PAT amplified by effective tax rate dropping to 29.4% from 35.9%
  • Operating margin ~14.7%, stepping down from Q4's ~17-18% in line with management's guided 'sustainable 15%+' normalisation as it funds growth investments
  • All four verticals grew YoY — BFSI +12.1% to ₹351.0 Cr; Life Sciences segment profit up to ₹51.7 Cr from ₹30.2 Cr QoQ; Manufacturing largest at ₹518.2 Cr but −1.6% QoQ
  • Consolidated EPS ₹5.72 vs ₹3.81 YoY; no exceptional item this quarter (prior ₹40.7 Cr labour-code charge was FY26 full-year only)
  • Standalone diverges sharply — revenue +32% YoY to ₹829.2 Cr, PAT nearly 4x to ₹146.8 Cr — reflecting intra-group flows, not underlying operations